C-Type Natriuretic Peptide (CNP) (1-22), human TFA

Name: C-Type Natriuretic Peptide (CNP) (1-22), human TFA
Brand: MedChemExpress
SKU: HY-P1237A
Rating: 5.0 (2 reviews)

製品番号: HY-P1237A 純度: 99.07%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

カスタムペプチド

C-Type Natriuretic Peptide (CNP) (1-22), human TFA 構造式

CAS 番号 : 1966153-17-2

容量	価格（税別）	在庫状況	数量
500 μg	$100	在庫あり	Estimated Time of Arrival: December 31
1 mg	$150	在庫あり	Estimated Time of Arrival: December 31
5 mg	$600	在庫あり	Estimated Time of Arrival: December 31
10 mg	$850	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Other Forms of C-Type Natriuretic Peptide (CNP) (1-22), human TFA:

C-Type Natriuretic Peptide (CNP) (1-22), human 在庫あり

顧客検証

Histamine Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

H₁ Receptor H₂ Receptor H₃ Receptor H₄ Receptor Histamine Receptor

Endothelin Receptor アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

ET_A ET_B

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[1]

NPR-B

体外実験

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human^[1]:

Dose (nM/kg)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	CL_tot (mL/min/kg)	Vd_ss (mL/kg)
20	320±54	1.02±0.18	1.42±0.45	63.9±11.9	64.2±5.1

PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human^[1]:

Dose (nM/kg)	Cmax (pM/mL)	Tmax (min)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	BA (%)
50	9.02±3.74	5.0±0.0	152±73	13.9±3.4	10.0±5.0	19±9

Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL_tot=total clearance, T_1/2=half-life period, BA=bioavailability.
C-Type Natriuretic Peptide (CNP) (1-22) ( i.c.v.) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

2311.62

分子式

C₉₅H₁₅₈F₃N₂₇O₃₀S₃

CAS 番号

1966153-17-2

Appearance

Solid

Color

White to off-white

Sequence Shortening

GLSKGCFGLKLDRIGSMSGLGC (Disulfide bridge: Cys6-Cys22)

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Sealed storage, away from moisture
Powder	-80°C	2 years
	-20°C	1 year
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (10.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (0.87 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.4326 mL	2.1630 mL	4.3260 mL
5 mM	0.0865 mL	0.4326 mL	0.8652 mL
10 mM	0.0433 mL	0.2163 mL	0.4326 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

純度とドキュメンテーション

純度: 99.07%

Select Batch:

データシート (272 KB) SDS (252 KB)

COA (242 KB) LCMS (100 KB) Elemental Analysis Report (101 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [Content Brief]

[2]. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. [Content Brief]

[3]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.4326 mL	2.1630 mL	4.3260 mL	10.8149 mL
	5 mM	0.0865 mL	0.4326 mL	0.8652 mL	2.1630 mL
	10 mM	0.0433 mL	0.2163 mL	0.4326 mL	1.0815 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.